The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Front-Line Treatment of Pancreatic Carcinoma with Gemcitabine (GMB) in Combination with Irinotecan (CPT-11): Preliminary Results of a Multicenter Phase II Study. 

Yoshitaka  Honma

Research Funding - AstraZeneca; Daiichi Sankyo; Merck Serono; Teijin Pharma

Yukihide  Kanemitsu

No Relationships to Disclose

Shinichi  Ohkawa

Honoraria - Lilly; Otsuka; Sandoz; Taiho Pharmaceutical; Yakult Honsha

Consulting or Advisory Role - Boehringer Ingelheim

Research Funding - AstraZeneca (Inst)

Hideaki  Kitahara

No Relationships to Disclose

Junki  Mizusawa

Honoraria - Chugai Pharma

Hiroshi  Katayama

No Relationships to Disclose

Kenichi  Nakamura

Honoraria - Eisai; Merck Serono; Nihonkayaku; Taiho Pharmaceutical

Junji  Furuse

Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha

Consulting or Advisory Role - Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical

Speakers' Bureau - Taiho Pharmaceutical

Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)

Yasuhiro  Shimada

Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha

Research Funding - Lilly Japan (Inst); Merck Serono (Inst); MSD K.K (Inst); Taiho Pharmaceutical (Inst)